Skip to main content
. 2011 May 23;13(4):630–635. doi: 10.1038/aja.2010.177

Figure 2.

Figure 2

(a) IPSS total score changes over time. Significant improvements with sildenafil and doxazosin GITS combined therapy (Group A) versus sildenafil monotherapy (Group B) were observed both at 3 and 6 months post-medication. (b) Moderate BPH/LUTS patients' IPSS score comparison between the two groups. In moderate BPH/LUTS patients (IPSS: 10–19), significant improvements with Group A versus Group B were observed both at 3 and 6 months post-medication. (c) Severe BPH/LUTS patients' IPSS score comparison between the two groups. In severe BPH/LUTS patients (IPSS ≥20), significant improvements with Group A versus Group B were observed at pre-medication, 3 and 6 months post-medication. (d) QoL total score changes over time. Significant improvements with Group A versus Group B were observed both at 3 and 6 months post-medication. *P<0.05, compared with Group B. BPH/LUTS, lower urinary tract symptoms secondary to benign prostatic hyperplasia; IPSS, International Prostate Symptom Score; Pre Tx, pre-treatment; QoL, quality of life.